Sab Bio

SAB Biotherapeutics is a biotechnology company based in the United States that specializes in developing fully human polyclonal antibody therapies using genetically engineered cattle. The company’s proprietary DiversitAb platform enables the production of large volumes of targeted antibodies for infectious diseases, immune disorders, and other medical conditions. SAB Biotherapeutics generates revenue through partnerships, government contracts, and licensing agreements, particularly in areas like pandemic preparedness and emerging infectious diseases. Founded in 2014, the company has played a notable role in rapid-response therapeutic development, including efforts during the COVID-19 pandemic. Candidates should be aware of SAB’s innovative approach to antibody production and its focus on addressing unmet medical needs through advanced biotechnological solutions.

Recent Posts by Sab Bio

1-20 of 61